Novartis’ Kisqali (ribociclib) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat a ...

Novartis UK announced the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised ribociclib for adjuvant ...

Aromatase inhibitors (AIs) are a class of drugs that block the aromatase enzyme, which is responsible for converting androgens (male hormones) into estrogens (female hormones). These medications ...

Trainer to face charges for presenting horse to the races twice in 2024 with several banned substances in his system ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.

Those receiving adjuvant endocrine therapy, including tamoxifen or aromatase inhibitors, for the treatment or prevention ... with previously conducted studies and published data on the drug in ...

Do innovator drugs work better than generic ... Ask the Pharmacists, November 2010 Can the Duration of Aromatase Inhibitor Therapy Exceed 5 Years? Does extended-duration aromatase inhibitor ...

Discussions also delved into the complexities of value-based oncology care, the growing role of real-world data, and strategies to improve access to care in hematology. Across all sessions, a common ...

when the SMC gave the green light for restricted prescribing of the drug in first-line HR+/HER2- breast cancer in combination with aromatase inhibitor drugs. Both are also trying to get the okay ...

For endocrine therapy, 90.9% received an aromatase inhibitor. Metzger and colleagues ... a HER2-positive indication with the US Food and Drug Administration based on the trial results.